Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ELDN stock here.

Rhythm Pharma (RYTM) surges on IMCIVREE sales growth and TRANSCEND data ahead of the March 20 FDA PDUFA decision—see risks, ...

Chief Executive Officer Mario Alberto Accardi told investors at the Leerink Partners Global Healthcare Conference that the company is aiming to establish its orexin-2 agonist program as a “best-in-cla ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

The latest issue of Current Pharmaceutical Analysis (Volume 22, Issue 2, March 2026) is now available online, featuring new open access articles on pharmaceutical methodologies, drug analysis, and ...

Corvus Pharmaceuticals (NASDAQ:CRVS) outlined expanding clinical plans for its selective ITK inhibitor soquelitinib while reporting higher research and development spending for 2025, reflecting a ...

Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra ...

Pharmaceutical companies in India are driving innovation, biosimilars, APIs & global exports while strengthening research, manufacturing & healthcare access.

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor ...

YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40 ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

Corvus Pharmaceuticals Inc. is set to report fourth-quarter results after the market close Thursday, with investors focused ...